How to appeal an Elevance Health prostate cancer denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Elevance Health-specific note: Operates Anthem BCBS in 14 states. Owns Carelon (formerly AIM) which manages utilization for specialty drugs and advanced imaging. State complaint route is to the state insurance department where the policy was issued.

What Elevance Health's policy requires for prostate cancer

Cited policy: BCBS Lynparza (Olaparib) for HRR-mutated Metastatic Castration-Resistant Prostate Cancer

Adult mCRPC with deleterious or suspected-deleterious germline OR somatic HRR mutation (FDA-approved test). HRR panel per PROfound: BRCA1, BRCA2, ATM, BRIP1, BARD1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, RAD54L. Prior progression on enzalutamide OR abiraterone (monotherapy indication). For PROpel combo (olaparib+abiraterone+prednisone): BRCA-mutated 1L mCRPC. Castrate testosterone <50 ng/dL. Olaparib 300 mg PO BID.

How Elevance Health denies prostate cancer — and how to counter it

Where Elevance Health pushes back: 1) Only BRCA1/2 covered; 2) HRR result must be germline only; 3) Insufficient ARSI failure for monotherapy.

Counter-arguments that hold up: PROfound NEJM 2020 Hussain — olaparib HRR-mutated mCRPC post-ARSI rPFS HR 0.34 (Cohort A BRCA/ATM) + 0.49 (overall HRR). FDA May 19, 2020 monotherapy label covers 14-gene HRR panel, NOT BRCA-only. Both germline AND somatic HRR mutations qualify per FDA label and NCCN v1.2025. PROpel NEJM Evid 2022 + Lancet 2023 — olaparib+abiraterone 1L mCRPC rPFS benefit (FDA narrowed combo label May 2023 to BRCA-mutated). NCCN v1.2025 Category 1 for HRR-mutated mCRPC post-ARSI.

What Elevance Health typically denies for prostate cancer

Across Elevance Health's commercial and Medicare books, denials cluster around a small number of patterns. For prostate cancer, expect:

• Step therapy
• Medical necessity for biologics
• Out-of-network for behavioral health
• Bariatric surgery prior auth

Treatments most often denied in this category

These are the prostate cancer treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Pluvicto (177Lu-PSMA-617)
• Xofigo (radium-223)
• Xtandi (enzalutamide)
• Erleada (apalutamide)
• Nubeqa (darolutamide)
• Zytiga (abiraterone)

How to submit the appeal to Elevance Health

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Elevance Health cited in the denial.
3. File the appeal through Elevance Health's portal (members: https://www.anthem.com ; providers: https://providers.anthem.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In IN, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Elevance Health's prior-authorization criteria by drug: Elevance Health PA criteria on ApprovalHelp.